Birmingham, October 2010
The Japanese pharmaceuticals and medical devices agency (PMDA) has approved Freelite nephelometric assays. The regulatory body of the Japanese ministry for Health, Labour and Welfare granted manufacturing approval from July 2010.
Freelite assays are manufactured and sold by Binding Site to measure free kappa and free lambda immunoglobulin light chains in serum. These quantitative, highly specific, automatable free light chain assays are already included in international guidelines for the diagnosis, prognosis and monitoring of multiple myeloma patients.
David Jackson, International Sales Manager of the Binding Site said
“Clinicians and multiple myeloma patients in Japan can now benefit from access to Freelite”
For more information log onto www.bindingsite.com or talk to your local Binding Site representative.